North China Pharmaceutical Co Ltd Total Assets
North China Pharmaceutical Co Ltd total assets. Based on the latest financial reports, North China Pharmaceutical Co Ltd (600812) holds total assets worth CN¥21.45 Billion CNY (≈ $3.14 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 600812 market cap overview for the company's overall valuation and market capitalisation.
Total Assets of North China Pharmaceutical Co Ltd (1993–2025)
Total assets of North China Pharmaceutical Co Ltd from 1993 to 2025. This chart illustrates how North China Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See North China Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
North China Pharmaceutical Co Ltd - Asset Composition Analysis
North China Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
North China Pharmaceutical Co Ltd total assets breakdown as of December 2025. North China Pharmaceutical Co Ltd's total assets of CN¥21.45 Billion consist of 38.0% current assets and 62.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.2% |
| Accounts Receivable | CN¥2.41 Billion | 11.3% |
| Inventory | CN¥2.41 Billion | 11.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥5.01 Billion | 23.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (1993–2025)
This chart illustrates how North China Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore North China Pharmaceutical Co Ltd (600812) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: North China Pharmaceutical Co Ltd's current assets represent 38.0% of total assets in 2025, an increase from 33.7% in 1993.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2025, up from 2.4% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 5.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 23.4% of total assets.
North China Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of North China Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
North China Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.72 | 0.73 | 0.97 |
| Quick Ratio | 0.51 | 0.53 | 0.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-3.17 Billion | CN¥-3.23 Billion | CN¥-463.10 Million |
North China Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between North China Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.55 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -0.4% |
| Total Assets | CN¥21.39 Billion |
| Market Capitalization | $1.20 Billion USD |
Valuation Analysis
Below Book Valuation: The market values North China Pharmaceutical Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: North China Pharmaceutical Co Ltd's assets decreased by 0.4% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for North China Pharmaceutical Co Ltd (1993–2025)
The table below shows the annual total assets of North China Pharmaceutical Co Ltd from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥21.39 Billion ≈ $3.13 Billion |
-0.37% |
| 2024-12-31 | CN¥21.47 Billion ≈ $3.14 Billion |
+2.46% |
| 2023-12-31 | CN¥20.96 Billion ≈ $3.07 Billion |
-1.25% |
| 2022-12-31 | CN¥21.22 Billion ≈ $3.11 Billion |
-14.88% |
| 2021-12-31 | CN¥24.93 Billion ≈ $3.65 Billion |
+4.17% |
| 2020-12-31 | CN¥23.93 Billion ≈ $3.50 Billion |
+29.07% |
| 2019-12-31 | CN¥18.54 Billion ≈ $2.71 Billion |
+3.48% |
| 2018-12-31 | CN¥17.92 Billion ≈ $2.62 Billion |
+4.46% |
| 2017-12-31 | CN¥17.15 Billion ≈ $2.51 Billion |
+4.10% |
| 2016-12-31 | CN¥16.48 Billion ≈ $2.41 Billion |
+2.99% |
| 2015-12-31 | CN¥16.00 Billion ≈ $2.34 Billion |
+2.78% |
| 2014-12-31 | CN¥15.56 Billion ≈ $2.28 Billion |
+6.90% |
| 2013-12-31 | CN¥14.56 Billion ≈ $2.13 Billion |
+7.53% |
| 2012-12-31 | CN¥13.54 Billion ≈ $1.98 Billion |
+20.19% |
| 2011-12-31 | CN¥11.27 Billion ≈ $1.65 Billion |
+23.53% |
| 2010-12-31 | CN¥9.12 Billion ≈ $1.33 Billion |
+24.92% |
| 2009-12-31 | CN¥7.30 Billion ≈ $1.07 Billion |
+3.74% |
| 2008-12-31 | CN¥7.04 Billion ≈ $1.03 Billion |
+5.48% |
| 2007-12-31 | CN¥6.67 Billion ≈ $976.30 Million |
-4.76% |
| 2006-12-31 | CN¥7.00 Billion ≈ $1.03 Billion |
0.00% |
| 2005-12-31 | CN¥7.01 Billion ≈ $1.03 Billion |
-7.97% |
| 2004-12-31 | CN¥7.61 Billion ≈ $1.11 Billion |
+4.78% |
| 2003-12-31 | CN¥7.26 Billion ≈ $1.06 Billion |
+4.39% |
| 2002-12-31 | CN¥6.96 Billion ≈ $1.02 Billion |
-5.13% |
| 2001-12-31 | CN¥7.34 Billion ≈ $1.07 Billion |
+22.84% |
| 2000-12-31 | CN¥5.97 Billion ≈ $873.76 Million |
+7.36% |
| 1999-12-31 | CN¥5.56 Billion ≈ $813.88 Million |
+41.88% |
| 1998-12-31 | CN¥3.92 Billion ≈ $573.64 Million |
+12.21% |
| 1997-12-31 | CN¥3.49 Billion ≈ $511.24 Million |
+25.72% |
| 1996-12-31 | CN¥2.78 Billion ≈ $406.66 Million |
+26.15% |
| 1995-12-31 | CN¥2.20 Billion ≈ $322.37 Million |
+18.90% |
| 1994-12-31 | CN¥1.85 Billion ≈ $271.12 Million |
+26.67% |
| 1993-12-31 | CN¥1.46 Billion ≈ $214.03 Million |
-- |
About North China Pharmaceutical Co Ltd
North China Pharmaceutical Company.Ltd engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company primarily offers anti-infective, biotechnology, and cardiovascular cerebrovascular drugs; and immunomodulators, vitamins, and health products. It also provides chemical, biological, agricultural, and biopharmaceuticals and veteri… Read more